Advanced Diagnosis and Management of OSD and Tear Dysfunction

Similar documents
Tear Structure. Structure = Stability. Disclosures. In Depth Management of Ocular Surface & Tear Film Disorders UNDERSTANDING THE OCULAR SURFACE

Dry Eye Disease Diagnosis and Treatment Pearls from the Trenches (2 hours) Mile Brujic, O.D Kensington Blvd. Bowling Green, OH 43402

Optimizing the Ocular Surface. Presentation Title. Charlene M. Grice, Carolina Eyecare Physicians, LLC

How to Create a Dry Eye Center

Title: Keeping Step with DEWS2: Clinical Applications Lecturer: Scott G. Hauswirth, OD

Financial Disclosures

1/16/2018. William D. Townsend, O.D., F.A.A.O. Advanced Eye Care Canyon, TX Adjunct Professor UHCO Houston, TX.

No Conflict of Interest to Report Charles Stockwell, O.D

Dry Eye Disease Update

D RY E YE C LINIC AT THE O FFICE OF D R. D AVID R. F RAZEE

Ocular Surface Disease Workshop Walter O. Whitley, OD, MBA, FAAO Michael Cooper, OD Whitney Hauser, OD Scott Hauswirth, OD, FAAO

1/23/2018. William D. Townsend, O.D., F.A.A.O. Advanced Eye Care Canyon, TX Adjunct Professor UHCO Houston, TX.

Consulting Bausch+Lomb/Valeant, NovaBay (Avenova), Google, Allergan, Vistakon, Alcon

IPL for the management of MGD/DED. Dr. Jeffrey Judelson, FRCSC

A DRY EYE DISEASE DECISION TREE

An Update on Diagnosis and Treatment of Refractory Ocular Surface Disease

Ophthalmic Immunomodulators Prior Authorization with Quantity Limit Program Summary

10/25/2017. Financial Disclosures. Evolution of Dry Eye Definition. Evolution of Dry Eye Definition. Tear Film and Ocular Surface Society (TFOS)

Current Treatment and Management of Dry Eye

Visionary Optics. SynergEyes. North Suburban Vision Consultants, Ltd. Keratoconus Specialists of Illinois. S. Barry Eiden, OD, FAAO

10/27/2017. Evidence for Technology in the Treatment of Dry Eye COPE: AS. Dry eye. Dry eye

Medical and/or Vision Insurance plans do not cover the Specialty Dry Eye Testing or LipiFlow services.

Learn Connect Succeed. JCAHPO Regional Meetings 2017

4/20/2014. Building Dry Eye Service Line. Mike Trier. Financial Disclosure. Approach of This Talk. Mike Trier No Financial Interest

Microblepharoexfoliation for the Surgical Dry Eye Patient. Frank W. Bowden, III, M.D., FACS

OCULAR SURFACE DISEASE SYNDROMES WAYNE ISAEFF, MD LOMA LINDA UNIVERSITY DEPARTMENT OF OPHTHALMOLOGY

Ocular Surface Disease. Advanced Treatment in Ocular Surface Disease. Disclosures. Revenue Potential. Chronic Dry Eye Should I Treat It

1998 DESCRIPTION Evaluation of Subjective and Objective tests for diagnosing tear-film disorders known to cause ocular irritation.

Meibomian Gland Dysfunction: What Does It Mean James P. McCulley, MD, FACS, FRCOph(UK)

The first comprehensive definition of DED was published in

Does in-office manual expression for Meibomian Gland Dysfunction (MGD) work?

Medical and/or Vision Insurance plans do not cover the Specialty Dry Eye Testing or LipiFlow services.

Dry Eye Assessment and Management Study ELIGIBILITY OCULAR EVALUATION FORM

Overview & pathophysiology of Dry Eye and the use of cyclosporine eye drops in dry eye...

Ophthalmology Times Case Study Yasmin Mali, MD. Case Study

Evidence for Technology in the Treatment of Advanced Dry Eye

Learning Objectives. Disclosures 2/2/ BMT Pharmacists Conference Bandage Contact Lens Therapy for Severe Ocular GVHD

9/26/2018 MANAGING THE LID MARGIN AND LASHES: IN-OFFICE PROCEDURES WHY OFFER IN-OFFICE PROCEDURES WHY OFFER IN-OFFICE PROCEDURES DISCLOSURES

Bruce H. Koffler, M.D. Lindsay Koffler Cassidy, COT, OSC

MANAGING THE LID MARGIN AND LASHES: IN-OFFICE PROCEDURES. Scott Schachter, OD Pismo Beach, CA

Strategies for Anterior Segment Disease Management Mile Brujic, OD, FAAO 1409 Kensington Blvd Bowling Green, OH

Breaking the Cycle. Yijie (Brittany) Lin, MD, MBA, Reena Garg, MD New York Eye and Ear Infirmary of Mount Sinai

MEIBOMIAN GLAND DYSFUNCTION & DRY EYE: WHAT DO THE EXPERTS SAY?

Understanding the Role of Meibomian Gland Dysfunction in Dry Eyes

Dry Eye Disease: Advancements in Therapy. Amanda Salter, M.D.

Pardon the Objection: Cases Marc R. Bloomenstein OD, FAAO Scot Morris, OD Derek Cunningham, OD Kathy Mastrota, OD

Bill Kilgore, LDO,NCLE,COA Virginia Mason Medical Center

Prevalence of Dry Eye Disease

The Tear Film! Cataract Surgery in the Diseased Eye: Ocular Surface Disease

Tear Osmolarity and its role in Optometric Practice & Contact Lens Success

Ocular Jeopardy Marc R. Bloomenstein OD, FAAO

During the last decade,

Professional Disclosures

Dry Eye and Related Corneal Issues. Outline. Dry Eye Syndrome (DES)

Dry eye syndrome. Lacrimal gland. Tear duct into nose. 1 of 6

Dr.Sushil Kumar Tripathi

Managing Dry Eye Disease

MANAGING THE LID MARGIN AND LASHES: IN-OFFICE PROCEDURES. Scott Schachter, OD Pismo Beach, CA

Eyelid Thermal Pulsation for the Treatment of Dry Eye Syndrome

OPHTHALMIC DOCTORATE

HELP HEAL YOUR PATIENTS DRY EYES.

Predisposing factors. Gender. Ocular Surface Disease. Ocular Surface Disease Health. Building a Dry Eye Practice

Immunology and Pathophysiology of Dry Eye

DRY EYE MANAGEMENT STRATEGIES: APPROPRIATE TREATMENT DECISION-MAKING IN PATIENTS WITH DRY EYE

A 5 Step Program. A 5 Step Program. A 5 step program. A 5 step Program 2/7/2018. A 5 Step Program Lens Settling Evidence.

DEWS. Dry Eye Evaluation. Dry eye is not just a disease, it s a complex, multifactorial 2/22/2016

BREAKING THE VICIOUS CIRCLE OF DRY EYE DISEASE

Diagnostics. Traditionally, clinicians have made the diagnosis. cover story. Join the renaissance!

Dry Eye That s Not Dry Eye

pat hways Medtech innovation briefing Published: 21 April 2015 nice.org.uk/guidance/mib29

Predisposing factors. Gender. Ocular Surface Inflammation and Infection Control. Ocular Surface Disease 8/7/12. Ocular Surface Disease Health

Evidence Based Approach Dry Eye Meibomian Gland Dysfunction

DRY EYE TAKING AIM. How Systematic Management of this Chronic Disease is Improving Patient Outcomes. Sponsored by. A Supplement to

New Advances in the Management of Lid Disease

Dry eye disease is multifactorial in aetiology and complex in pathophysiology that makes its diagnosis clinically challenging.

DRY EYE and MGD. Contact Central Maryland Eye Associates Today.

Correlation of Bacterial Burden, Meibomian Gland Dysfunction and Ocular Surface Disease

Fitting Keratoconus and Other Complicated Corneas

Date Initials Comments

IMPACT OF EVAPORATION ON AQUEOUS TEAR LOSS

Meibomian gland dysfunction

Question 1: Discuss your further examination of this patient with respect to her current symptoms

Subject Index. Atopic keratoconjunctivitis (AKC) management 16 overview 15

Spontaneous Eye Blink Patterns in Dry Eye: Clinical Correlations

5/11/2015. Hallway controversies in ocular surface disease. Hallway controversies in ocular surface disease. Disclosures

Evaluation of Dry Eye: A Hospital Based Study

Dry eye disease was recently redefined as a multifactorial

Although the prevalence

Dry Eye Prescribing Guidelines

DRY EYE DISEASE CE MONOGRAPH FACULTY. Original Release: July 24, 2017 Expiration: July 24, 2020

Case no.4. Subjective. Subjective (2) Caucasian female, 62 Y.O., consulting for a XXX opinion on her condition.

Meibomian gland Dropout in Chinese cataract patients.

Scottish Dry Eye Guidelines

Index. Springer International Publishing AG 2018 A.R. Djalilian (ed.), Ocular Surface Disease,

pat hways Medtech innovation briefing Published: 15 December 2015 nice.org.uk/guidance/mib47

Improve the Diagnosis, Management and Treatment of Inflammatory Dry Eye

Meibomian gland dysfunction (MGD) may well be the leading

Dry Eye Syndrome. US Drug Forecast and Market Analysis to GDHC1115CFR / Published May 2013

PRESUMED HYPOSECRETORY/HYPEREVAPORATIVE KCS: TEAR CHARACTERISTICS

Transcription:

Advanced Diagnosis and Management of OSD and Tear Dysfunction Arthur B. Epstein, OD, FAAO Phoenix, Eye Care & The Dry Eye Center of Arizona Phoenix, AZ, USA Our understanding of the ocular surface has evolved dramatically over the past few years. Growing interest in dry eye and tear dysfunction has increased interest in this practice segment. We apply an evidence-based approach with extensive use of video animation, to integrate novel concepts into a unified perspective of the ocular surface environment with direct practical and clinical diagnostic and therapeutic application. Current therapy is reviewed with specific focus on dogma vs. newer concepts and clinical approaches that contrast traditional palliative therapies to newer approaches that target root causes and functional issues. Course Outline I. Overview of the current theories of ocular surface and tear layer a. Current thinking on surface anatomy and physiology i. The structure of the ocular surface ii. Interaction with the tear components b. Support for primary functions of the tear structure c. Balance and homeostasis of the ocular environment II. Historical perspective and evolution of knowledge a. Previous theories i. Sjögren (1940) - Identified and defined keratoconjunctivitis sicca ii. Wolff (1946): Tri-layer tear film iii. Holly & Lemp (1973): Expanded understanding of mucin b. Contemporary thinking i. Scheffer C.G. Tseng (1997): Surface and tear film interaction 1. The preocular tear film and the ocular surface function as a unit 2. The external adnexa maintains tear film stability 3. Intact innervation is critical to ocular surface health a. Corneal epithelial limbal stem cells play a critical role 4. The underlying basement membrane and stromal fibroblasts support surface health and function ii. Donald Korb (1980 & 2002-Present): MGD, Role of lipids & Lid Wiper Epitheliopathy iii. David Meadows (2004): Tear film memory & biochemical complexity of the tear film iv. Kelly Nichols MGD Workshop (2011) MGD and EDE

III. Anatomy and Physiology of the Ocular Surface a. Ocular surface adaptations that support tear function i. Surface tear interaction b. The importance of surface area and surface morphology i. Role of microvilli and glycocalix 1. Transforming hydrophobic to hydrophilic 2. Structural aspects of the tears c. Tear components and structure i. Adhesive qualities of mucins 1. Trans-membrane mucins ii. Viscoelastic properties of the tears 1. Cohesion and regularity a. Tear film memory 2. Cushioning a. Fluid mechanics of the tear i. Newtonian vs. non-newtonian fluids b. Surface protection and regularity d. Lubricity and barrier function i. The critical importance of lipids to tear film function 1. Oil and water don t mix 2. Lipid serves as an evaporative and functional barrier 3. Lipid layer complexities a. Non-polar lipids b. Phospholipids i. Bind the lipid layer to underlying gel forming mucins e. The lids are a source of energy and motion IV. The tear film exists as a complex interwoven system a. Balance is an essential requirement for maintenance of the ocular surface i. Disturbance to one element can affect all of the others ii. The normal ocular surface is stable iii. The body seeks to restore a normal state V. The critical importance of tear stability a. The elements of stability b. Disruptors of stability VI. Contact lenses and the ocular environment a. How contact lenses promote surface drying b. Insight into the contact lens surface and relationship to the ocular environment c. Silicone hydrogel and lipid depletion VII. Surface disease diagnostic testing a. Tear film and OSD testing i. Surface staining patterns ii. Break-up time 1. Etiology a. Inside out vs. outside in? iii. Osmolarity

iv. Lipid layer & MG testing 1. Interferometry 2. Expression a. MGE b. Mastrota paddle 3. Meibography v. Break up time FBUT NIBUT 1. Automated - Oculus Keratograph 5M vi. Other testing VIII. Surface Disorder Pathophysiology a. Etiology i. Tear dysfunction 1. Evaporative dry eye relative importance 2. Aqueous deficiency a. Evaporative b. Secretion issues i. Systemic vs. local disease 3. Tear stagnation 4. Punctal stenosis 5. Conjunctival chalasis ii. Inflammation iii. Staph and other microbial disease related to DES iv. Neurotrophic disease v. Surface disruption 1. Staining 2. Loss of normal morphology vi. Lid abnormalities and disorders 1. Decreased or ineffective blinking 2. Excessive blinking 3. Anatomical/functional problems of the lid vii. Delayed Tear Clearance viii. Surface abnormality 1. Conjunctival chalasis ix. LWE x. Meibomian gland dysfunction 1. Among the most prevalent of all ocular disease a. Evaporative component in 87% of all dry eye patients 2. Progressive 3. Inflammatory cascade locally and within ocular surface environment IX. Diagnosis a. Conventional approaches i. Subjective 1. Questionnaires and Surveys a. OSDI b. SPEED

ii. Meibomian gland evaluation 1. Diagnostic expression 2. Korb MGE 3. Transillumination iii. Staining 1. Fluorescein 2. Rose Bengal 3. Lissamine Green iv. FTFBUT v. Schirmer testing vi. Tear prism assessment vii. Examination of lid gap 1. Bells phenomenon b. Advanced Technology i. Lipiview ii. Keratograph K5M 1. Meibography 2. NIBUT iii. TearLab Osmolarity iv. RPS Inflmadry X. Etiology Based Treatment a. Management of MGD i. IPL ii. Probing iii. Lipiflow iv. MiBo Theroflow v. Conventional therapy 1. Technique 2. Compliance 3. Cautions b. Palliative (mostly OTC but different approaches for different etiologies) i. Balanced approaches ii. Normalization of osmolarity iii. Other strategies c. Restorative i. Mucomimetics ii. Secretagogues iii. Lipid supplementation iv. Tear retention strategies 1. Punctal Plugs 2. Cautery v. Amniotic membrane lenses and grafts vi. Bandage lenses vii. PROSE and Scleral lenses viii. Surgical approaches d. Anti-inflammatory i. Cyclosporine ii. Steroids

iii. Emerging medications Arthur Epstein is a consultant for Alcon Laboratories, B+L, BioD, BioTissue, NovaBay, Oculus, PRN Pro Omega Health, Science Based Health, Shire, TearLab and Vistakon.